Aprea Therapeutics (APRE) Stock Price, News & Analysis

Company Overview

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing therapies that target the p53 tumor suppressor pathway, one of the most frequently altered pathways in human cancer. Its lead investigational agent, eprenetapopt (APR-246), is designed to restore wild‐type function to mutant p53 protein, triggering cancer cell death and enhancing the efficacy of existing anti‐cancer therapies. Aprea’s research focuses primarily on hematologic malignancies and solid tumors where p53 mutations drive disease progression.

The company’s pipeline includes eprenetapopt in combination with azacitidine for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), with ongoing clinical studies evaluating safety, tolerability and clinical benefit. In parallel, Aprea is exploring novel compounds that act synergistically with eprenetapopt, aiming to expand its therapeutic reach across a broader spectrum of p53‐mutant cancers. Preclinical programs also investigate the role of p53 reactivation in immuno‐oncology, with the goal of combining targeted therapies and immune checkpoint inhibitors.

Founded in 2013, Aprea has its headquarters in Redwood City, California and maintains a research site in Stockholm, Sweden, reflecting its transatlantic scientific collaborations. The company emerged from pioneering academic work on small molecules that stabilize mutant p53 and leverages partnerships with leading research institutions and pharmaceutical companies to advance its clinical programs. Aprea completed its initial public offering on the NASDAQ exchange in 2017, providing capital to support ongoing and future studies.

Under the leadership of President and CEO Ullrich Graedler, Aprea’s management team brings together expertise in oncology drug development, regulatory affairs and commercial strategy. The company’s multidisciplinary leadership is supported by a scientific advisory board composed of experts in molecular oncology and translational medicine. Aprea continues to pursue collaborations and strategic alliances to accelerate the development and potential approval of its p53‐based therapies worldwide.

Key Stats

• Today's Range: $1.76 to $1.97
• 50-Day Range: $1.50 to $1.94
• 52-Week Range: $1.41 to $5.01
• Volume: 51,533 shs
• Average Volume: 26,657 shs
• Market Capitalization: $9.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.50
• Consensus Rating: Buy

Aprea Therapeutics Stock Analysis - MarketRank™

Aprea Therapeutics scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aprea Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.55) to ($0.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aprea Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aprea Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aprea Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.51% of the float of Aprea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aprea Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aprea Therapeutics has recently decreased by 1.09%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aprea Therapeutics does not currently pay a dividend.

Dividend Growth

Aprea Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.51% of the float of Aprea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aprea Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aprea Therapeutics has recently decreased by 1.09%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

MarketBeat Follows

Only 1 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aprea Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.63% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 34.19% of the stock of Aprea Therapeutics is held by institutions.

APRE Stock Analysis - Frequently Asked Questions

How have APRE shares performed this year?

Aprea Therapeutics' stock was trading at $3.29 at the start of the year. Since then, APRE stock has decreased by 46.2% and is now trading at $1.77.

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.01. The company had revenue of $0.16 million for the quarter. Aprea Therapeutics had a negative trailing twelve-month return on equity of 68.39% and a negative net margin of 1,095.02%.

When did Aprea Therapeutics' stock split?

Aprea Therapeutics shares reverse split on the morning of Monday, February 13th 2023.The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Aprea Therapeutics IPO?

Aprea Therapeutics (APRE) raised $52 million in an initial public offering on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

How do I buy shares of Aprea Therapeutics?

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APRE
• CIK: 1781983
• Web: www.aprea.com
• Phone: 617-463-9385
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aprea Therapeutics: $15.50
• High Price Target: $20.00
• Low Price Target: $11.00
• Potential Upside/Downside: +775.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.96 million
• Net Margins: -1,095.02%
• Pretax Margin: -1,095.02%
• Return on Equity: -68.39%
• Return on Assets: -55.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.90
• Quick Ratio: 5.90

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.55 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 5,531,000
• Free Float: 4,777,000
• Market Cap: $9.79 million
• Optionable: No Data
• Beta: 1.19